Change of safety interval from hyperviscosity problem in COVID-19 vaccine recipient with underlying diabetic problem
Guardado en:
Autores principales: | Pathum Sookaromdee, Viroj Wiwanitkit |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wolters Kluwer Medknow Publications
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/16549c0c94e54b9b9db27c4710432494 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Living-donor parathyroid cells allotransplantation in a kidney transplant recipient – Two-year results
por: Vladimir Khryshchanovich, et al.
Publicado: (2021) -
Applying a women's health lens to endocrine and metabolic disorders
por: Usha Sriram
Publicado: (2021) -
Prevalence of frailty in middle-aged diabetic population of Ahmedabad: A cross-sectional study
por: Priyal P Bhatt, et al.
Publicado: (2021) -
Diabetes, COVID-19 and mucormycosis: Unanswered questions!
por: Ashu Rastogi, et al.
Publicado: (2021) -
When the DHOL is beating, BHANGRA comes to the rescue!
por: Gagan Priya, et al.
Publicado: (2021)